Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioPER palbociclib rechallenge in ER-positive metastatic breast cancer
2015-003892-31Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in breast cancer, sponsored by MEDSIR. Primary endpoints: Biological endpoint and Clinical endpoint. Started Feb 2017; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-003892-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003892-31.